Rengalin, 100 ml

It was shown experimentally that the drug components modify the activity of ligand-receptor interaction of endogenous regulators with the corresponding receptors: antibodies to morphine – with opiate receptors; antibodies to histamine – with H1-histamine receptors; antibodies to bradykinin – with B1-bradykinin receptors; the combined use of components leads to a stronger anti-cough effect.

In addition to the anti-coughing effect, the complex drug due to its components has anti-inflammatory, anti-edema, anti-allergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic effect (antibodies to morphine).

Complex preparation Rengalin due to modification of histamine-dependent activation of H1-receptors and bradykinin-dependent activation of B2-receptors selectively decreases excitability of the medulla oblongata cough center and inhibits central links of the cough reflex. Inhibiting centers of pain sensitivity in the thalamus, blocks the transmission of pain impulses to the cerebral cortex. Inhibits the flow of pain impulses from the periphery by reducing the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc.). Unlike narcotic analgesics it does not cause respiratory depression, drug addiction, has no narcogenic and hypnotic effect.

Relieves symptoms of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. Cures systemic and local symptoms of allergic reactions due to the effect on the synthesis and release of histamine and bradykinin from mast cells.

Indications

Rengalin® is indicated for use in adults and children over 3 years of age.
Productive and non-productive cough with influenza and ARVI, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis, chronic obstructive pulmonary disease and other infectious-inflammatory and allergic diseases of the upper and lower respiratory tract.

Pharmacological effect

Pharmacotherapeutic group

Other antitussive drugs.

ATX code

R05DB.

Pharmacological properties

Pharmacodynamics

It has been experimentally shown that the components of the drug modify the activity of the ligand-receptor interaction of endogenous regulators with the corresponding receptors: antibodies to morphine (a component of the drug) modify the activity of the ligand-receptor interaction of endogenous regulators with opiate receptors; antibodies to histamine –
with H1 histamine receptors; antibodies to bradykinin – with bradykinin receptors; in this case, the combined use of the components leads to an increase in the antitussive effect.

In addition to the antitussive effect, the complex drug, due to its constituent components, has anti-inflammatory, decongestant, antiallergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic effects (antibodies to morphine).

Complex drug Rengalin® due to modification of histamine-dependent activation of H1 receptors and bradykinin-dependent activation of B1 and
B2 receptors selectively reduces the excitability of the cough center of the medulla oblongata and inhibits the central links of the cough reflex. By inhibiting pain sensitivity centers in the thalamus, it blocks the transmission of pain impulses to the cerebral cortex. Inhibits the flow of pain impulses from the periphery due to a decrease in the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc.). Unlike narcotic analgesics, it does not cause respiratory depression, drug dependence, and does not have a narcotic or hypnotic effect.

Alleviates the manifestations of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. Relieves systemic and local symptoms of allergic reactions by influencing the synthesis and release of histamine and bradykinin from mast cells.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active ingredients of the drug Rengalin® in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Special instructions

Patients with rare hereditary fructose intolerance should not take this drug.

If necessary, combination with mucolytics is possible.

Patients with diabetes should remember that every teaspoon
(5 ml) of the drug contains 0.3 g of maltitol, which corresponds to 0.02 bread units (XU). Insulin is required for the metabolism of maltitol, although due to slow hydrolysis and absorption in the gastrointestinal tract, the need for insulin is low. The energy value of maltitol is 10 kJ or 2.4 kcal/g, which is significantly less than that of sucrose. The energy value of one teaspoon of the drug is approximately 5.7 kJ (1.37 kcal).

Impact on the ability to drive vehicles and machinery

Not studied.

Composition

Active ingredients:

antibodies to bradykinin, affinity purified – 2,000 EMD*,

affinity purified antibodies to histamine – 2,000 EMD*,

affinity purified antibodies to morphine – 2,000 EMD*.

Excipients: hypromellose, maltitol, glycerol, potassium sorbate, anhydrous citric acid, purified water.

* EMD – units of modifying action.

Pregnancy

The safety of using Rengalin® in pregnant women and during breastfeeding has not been studied. During pregnancy and breastfeeding, the drug is used only if the expected benefit to the mother outweighs the potential risk to the fetus and child. The benefit/risk ratio is determined by the attending physician.

Contraindications

Children under 3 years of age.
Increased individual sensitivity to the components of the drug.
Hereditary fructose intolerance (due to the presence of maltitol).

With caution
Diabetes mellitus.

Side Effects

Reactions of increased individual sensitivity to the components of the drug are possible.
If these side effects get worse or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

During the clinical studies conducted, no data were obtained on the interaction of the drug Rengalin® with drugs used as concomitant therapy.

Overdose

In case of overdose, dyspeptic symptoms (nausea, vomiting, diarrhea) are possible due to the excipients included in the drug (maltitol, glycerol).
Treatment is symptomatic.

Short product description

Rengalin is a drug for the treatment of productive and non-productive cough in adults and children from 3 years of age

Storage conditions

At a temperature not exceeding 25 °C.
After opening, store the bottle at a temperature not exceeding 25 °C for 35 days.
Keep out of the reach of children.
Do not freeze.

Shelf life

3 years

Do not use after expiration date.

Manufacturer

Materia Medica Holding, Russia